Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Oral IL-23 Inhibitor (Psoriasis/IBD) Market: Icotrokinra Commercial Launch Demand, High-Impact-Site Clearance Growth, and Head-to-Head Biologic Superiority Adoption to Drive Exceptional Market Expansion Through 2035

The global Oral IL-23 Inhibitor (Psoriasis/IBD) Market is projected to expand at an exceptional CAGR of 30.4% through 2035, driven by sustained commercial demand following icotrokinra’s March 2026 FDA approval, growing evidence supporting high-impact-site skin clearance in scalp and genital psoriasis, and continued development of head-to-head trials demonstrating superiority over injectable biologics. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises icotrokinra (Icotyde), the first and only FDA-approved oral IL-23 receptor-targeted peptide, alongside AVR-001, SOR102, and other next-generation oral IL-23 inhibitor candidates in earlier development.

The market’s exceptional 30.4% CAGR reflects a landmark March 18, 2026 FDA approval establishing the first oral targeted peptide for moderate-to-severe plaque psoriasis: icotrokinra’s Phase 3 ICONIC program demonstrated approximately 65% to 70% IGA 0/1 clear-or-almost-clear skin response and approximately 50% to 55% PASI 90 response at week 16, with safety remaining within 1.1 percentage points of placebo through week 16 and no new safety signals through week 52. In its ICONIC-TOTAL study addressing high-impact disease sites, icotrokinra achieved clear or almost clear skin in 72% of patients with scalp psoriasis and 85% with genital psoriasis at week 52, while its ICONIC-ADVANCE head-to-head trials demonstrated superiority over the oral TYK2 inhibitor deucravacitinib, and its ongoing ICONIC-ASCEND study represents the first trial designed to test oral superiority over an injectable biologic. Coverage extending across multiple molecular types, mechanisms, and disease sites underscores the breadth of clinical and commercial infrastructure now supporting this newly approved and rapidly expanding category.

Executive Snapshot

How does icotrokinra’s commercial launch demand drive the oral IL-23 inhibitor market?
Dermatology clinics continue to prescribe icotrokinra following its March 2026 FDA approval for adults and adolescents aged 12 years and older, supported by ICONIC Phase 3 data showing approximately 65% to 70% clear-or-almost-clear skin response at week 16, establishing this landmark approval as the central driver of current market activity. As commercial adoption continues to expand, procurement associated with this first-in-class oral IL-23 receptor antagonist is expected to remain the dominant category through the forecast period.

What role does high-impact-site clearance growth play in market expansion?
Dermatology clinics increasingly value icotrokinra’s demonstrated efficacy in high-impact sites, with the ICONIC-TOTAL study showing 72% clear-or-almost-clear skin in scalp psoriasis and 85% in genital psoriasis at week 52, sustaining structured demand from clinicians pursuing treatment options for these historically difficult-to-treat and quality-of-life-impacting disease manifestations.

How does head-to-head biologic superiority adoption sustain market growth?
Biopharmaceutical developers and dermatology clinics continue to monitor icotrokinra’s ongoing ICONIC-ASCEND trial, the first study designed to demonstrate oral agent superiority over an injectable biologic in psoriasis, sustaining structured demand from clinicians and patients pursuing evidence supporting oral therapy as a viable alternative to conventional injectable biologic treatment.

What is driving demand for oral IL-23 inhibitors in inflammatory bowel disease applications?
Developers pursuing icotrokinra and related candidates for ulcerative colitis, where icotrokinra has already met its primary clinical response endpoint in a Phase 2/3 study, continue to extend oral IL-23 receptor antagonism beyond psoriasis into broader immune-mediated inflammatory disease applications, generating incremental demand among gastroenterology and biopharmaceutical developers.

How does once-daily oral peptide formulation demand sustain the market?
Dermatology clinics increasingly favor icotrokinra’s once-daily oral macrocyclic peptide formulation, sustaining structured demand from patients and clinicians pursuing this convenient administration approach relative to injectable IL-23 and IL-17 biologics requiring periodic office or self-administered injections.

Which oral IL-23 inhibitor market segments are growing fastest?
The fastest-growing segments include high-impact-site indications including scalp and genital psoriasis, inflammatory bowel disease applications, adolescent patient populations following expanded labeling, and head-to-head positioning against injectable biologics.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Oral IL-23 Inhibitor (Psoriasis/IBD) Market

  • Clinical trial data snapshot sustaining the evidentiary foundation for the category’s growth outlook: Icotrokinra’s ICONIC Phase 3 program showed approximately 65-70% IGA 0/1 clearance and approximately 50-55% PASI 90 response at week 16, with 72% scalp and 85% genital psoriasis clearance at week 52, safety within 1.1 percentage points of placebo through week 16, and demonstrated superiority over deucravacitinib in head-to-head trials.
  • Icotrokinra sustaining the entirety of current commercial market activity as the category’s sole approved product: As the first and only FDA-approved oral IL-23 receptor-targeted peptide, icotrokinra continues to anchor the substantial majority of current market activity.
  • Moderate-to-severe plaque psoriasis sustaining the primary current approved indication: This established regulatory pathway continues to anchor commercial demand as the category’s first validated application.
  • High-impact disease sites sustaining structured demand growth as a key clinical differentiator: Scalp and genital psoriasis clearance data continue to support treatment center adoption for these historically challenging disease manifestations.
  • Oral macrocyclic peptide chemistry sustaining a mechanistically distinct commercial position relative to injectable biologics: This first-in-class molecular approach continues to differentiate icotrokinra from conventional IL-23 and IL-17 monoclonal antibody therapies.
  • Inflammatory bowel disease applications sustaining structured demand growth as an emerging indication beyond psoriasis: Positive Phase 2/3 ulcerative colitis data continue to broaden the category’s addressable therapeutic indication scope.

Market Segmentation: Oral IL-23 Inhibitor (Psoriasis/IBD) Market

By Product Type
  • Icotrokinra (JNJ-2113 / Icotyde)
  • AVR-001
  • SOR102
  • Others
By Molecular Type
  • Oral Peptide
  • Oral Small Molecule
  • Macrocyclic Molecule
  • Engineered Peptide
  • Others
By Mechanism of Action
  • IL-23R Antagonism
  • IL-23 Ligand Neutralization
  • IL-23 Signaling Blockade
  • IL-23–Mediated Th17 Suppression
  • Downstream IL-17 Pathway Modulation
  • Dual Cytokine Pathway Inhibition
By Target
  • IL-23 Receptor (IL-23R)
  • IL-23 p19 Subunit
  • IL-23 / IL-12 Shared Pathway
  • Dual IL-23 / Other Cytokine Target
  • Others
By Therapeutic Area
  • Psoriasis
  • Inflammatory Bowel Disease
    • Ulcerative Colitis
    • Crohn’s Disease
  • Psoriatic Arthritis
  • Other
By Disease Stage
  • Mild
  • Moderate
  • Moderate-to-Severe
  • Severe
  • Refractory / Treatment-Resistant
By Patient Type
  • Adult Patients
  • Geriatric Patients
  • Pediatric Patients
By Dosing Frequency
  • Once Daily
  • Twice Daily
  • Once Weekly
  • Biweekly
  • Monthly
  • Others
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Dermatologists
  • Gastroenterologists
  • Rheumatologists
  • Specialty Clinics
  • Hospitals
  • Academic Medical Centers
  • Specialty Pharmacies
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Oral IL-23 Inhibitor (Psoriasis/IBD) Market

  1. Sustained commercial launch of the first oral IL-23 receptor antagonist driving continued market adoption: Icotrokinra’s landmark approval continues to support structured demand above the discretionary specialty pharmaceutical baseline.
  2. Growing clinical evidence supporting high-impact-site efficacy driving expanded treatment center adoption: Scalp and genital psoriasis clearance data continue to attract structured demand from dermatology clinics treating these challenging manifestations.
  3. Continued head-to-head trial development supporting oral therapy positioning against injectable biologics: The ICONIC-ASCEND program continues to generate structured interest in establishing oral superiority over conventional biologic treatment.
  4. Sustained extension into inflammatory bowel disease broadening the addressable therapeutic market: Positive ulcerative colitis data continue to generate incremental demand among gastroenterology-focused biopharmaceutical developers.
  5. Growing patient and clinician preference for oral administration supporting convenience-driven adoption: Once-daily oral dosing continues to attract structured demand relative to injectable IL-23 and IL-17 biologic alternatives.
  6. Maturing clinical pipeline supporting anticipated additional indication approvals and label expansions: Continued Phase 2/3 development across additional immune-mediated inflammatory diseases continues to focus industry attention on the category’s next phase of expansion.

Regional Outlook: Oral IL-23 Inhibitor (Psoriasis/IBD) Market

  • North America: The United States accounts for the largest share of regional demand, anchored by icotrokinra’s March 2026 FDA approval and extensive dermatology clinic infrastructure; regional treatment centers continue to expand prescribing capacity following this landmark approval.
  • Europe: Germany, France, and the United Kingdom anchor regional demand, supported by growing specialized dermatology center capacity and anticipated regulatory review of icotrokinra; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets as treatment access expands and regional biopharmaceutical developers advance their own oral IL-23 inhibitor pipelines; regional treatment centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized dermatology centers begin to prepare for oral IL-23 inhibitor access; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Oral IL-23 Inhibitor (Psoriasis/IBD) Market

Key Players
Johnson & Johnson, AbbVie Inc., Bristol Myers Squibb Company, Sun Pharmaceutical Industries Limited, Protagonist Therapeutics, Inc.

  • Johnson & Johnson [March 2026] — confirmed FDA approval of icotrokinra (Icotyde) for moderate-to-severe plaque psoriasis in adults and adolescents, with the company noting this represents the first oral targeted peptide approved for the condition.
  • Johnson & Johnson [October 2025] — reported long-term ICONIC-TOTAL results showing durable skin clearance in scalp and genital psoriasis, with the company noting sustained favorable safety profile through week 52 of treatment.
  • Johnson & Johnson [September 2025] — confirmed icotrokinra’s superiority over deucravacitinib in the head-to-head ICONIC-ADVANCE studies, with the company noting continued enrollment in its ICONIC-ASCEND trial versus an injectable biologic comparator.

Consultant POV

The Oral IL-23 Inhibitor (Psoriasis/IBD) Market’s exceptional 30.4% CAGR outlook through 2035 is anchored in sustained icotrokinra commercial launch demand, growing high-impact-site clearance activity, and continued head-to-head biologic superiority adoption. Sustained clinical and commercial investment from companies including Johnson & Johnson, AbbVie Inc., and Protagonist Therapeutics, Inc. confirms the Oral IL-23 Inhibitor Market will sustain exceptional growth through 2035 following its landmark first approval.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report